Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genomic Research Center, |
RCV001169991 | SCV001251807 | uncertain significance | Schwartz-Jampel syndrome | 2020-05-03 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001859100 | SCV002268266 | uncertain significance | not provided | 2022-05-28 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with HSPG2-related conditions. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). ClinVar contains an entry for this variant (Variation ID: 915382). This variant is present in population databases (rs558798136, gnomAD 0.03%). This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 397 of the HSPG2 protein (p.Arg397Gln). |
Ambry Genetics | RCV002558698 | SCV003719064 | uncertain significance | Inborn genetic diseases | 2021-12-07 | criteria provided, single submitter | clinical testing | The c.1190G>A (p.R397Q) alteration is located in exon 9 (coding exon 9) of the HSPG2 gene. This alteration results from a G to A substitution at nucleotide position 1190, causing the arginine (R) at amino acid position 397 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |